Psychedelics Federal Scheduling: DEA Classifications and Legal Status

Executive Summary

The Drug Enforcement Administration (DEA) is moving to place several psychedelic compounds under Schedule I of the Controlled Substances Act, even as the Food and Drug Administration (FDA) takes steps to accelerate legal access to psychedelic-assisted therapies. This regulatory collision, unfolding in September 2026, highlights the fundamental tension between federal drug control policy and emerging medical evidence for psychedelic treatments. The DEA's proposed scheduling actions target novel tryptamines and phenethylamines that have appeared in research contexts, while the FDA recently held a historic public hearing on September 16, 2026, exploring pathways to expand access to psychedelic therapies for mental health conditions including treatment-resistant depression, post-traumatic stress disorder, and substance use disorders. The divergent approaches from two federal agencies within the same administration underscore the fractured federal framework governing psychedelics, creating uncertainty for researchers, pharmaceutical companies, healthcare providers, and the estimated 21 million American adults who could benefit from novel psychiatric treatments according to National Institute of Mental Health data.

Why This Matters

The scheduling decisions the DEA makes in 2026 will determine whether promising psychiatric treatments reach patients or remain locked behind criminal prohibitions for another generation. This regulatory conflict affects multiple stakeholder groups with billions of dollars and millions of lives in the balance. For the psychedelic pharmaceutical industry, which attracted more than $2.4 billion in venture capital investment between 2019 and 2025 according to Psychedelic Alpha market data, Schedule I placement creates insurmountable research barriers. Companies developing MDMA-assisted therapy, psilocybin treatments, and novel psychedelic compounds face DEA registration requirements, quota limitations, and security protocols that add $500,000 to $2 million annually to research costs. For patients, the stakes are even higher. An estimated 17.3 million American adults experienced a major depressive episode in 2025 according to the Substance Abuse and Mental Health Services Administration, with approximately 30 percent showing treatment-resistant depression that fails to respond to conventional antidepressants. Veterans comprise another critical population, with the Department of Veterans Affairs reporting that 13 veterans die by suicide daily, many after exhausting standard PTSD treatments. Clinical trials have shown that MDMA-assisted therapy produces a 71 percent response rate for chronic PTSD, compared to 48 percent for placebo with therapy, according to Phase 3 data published in Nature Medicine. Healthcare systems face mounting costs from psychiatric conditions. The National Alliance on Mental Illness estimates that serious mental illness costs the United States $193.2 billion annually in lost earnings alone, not counting direct treatment costs or social services. State governments in Oregon, Colorado, and California have already invested tens of millions in psychedelic therapy infrastructure, creating a federalism conflict if the DEA schedules compounds that states are legalizing.

Background and History: From Prohibition to Medical Renaissance

The federal scheduling of psychedelics began in 1970 with the Controlled Substances Act, ending a brief period of legitimate psychiatric research and initiating a five-decade prohibition.

The First Wave: 1950s-1960s Medical Research

Between 1950 and 1965, researchers published more than 1,000 clinical papers on psychedelic therapy, studying LSD and mescaline for alcoholism, depression, and end-of-life anxiety. The Central Intelligence Agency's Project MKUltra, which ran from 1953 to 1973, conducted unethical experiments with LSD on unwitting subjects, creating public backlash that would taint legitimate research for decades. Sandoz Pharmaceuticals distributed LSD to researchers worldwide under the brand name Delysid, and psychiatrists including Humphry Osmond and Abram Hoffer reported promising results treating alcoholism in Saskatchewan. The cultural explosion of recreational psychedelic use in the mid-1960s, combined with anti-war activism and countercultural movements, prompted political backlash. Timothy Leary's advocacy for widespread LSD use and his 1966 founding of the League for Spiritual Discovery brought psychedelics into the culture war. California banned LSD in October 1966, followed by federal restrictions.

The Controlled Substances Act and Schedule I Placement

Congress passed the Controlled Substances Act as Title II of the Comprehensive Drug Abuse Prevention and Control Act of 1970, signed by President Richard Nixon on October 27, 1970. The Act created five schedules based on medical utility, abuse potential, and safety. Schedule I, defined in 21 U.S.C. § 812(b)(1), requires three findings: high potential for abuse, no currently accepted medical use in treatment in the United States, and lack of accepted safety for use under medical supervision. The DEA placed LSD, psilocybin, psilocin, mescaline, and DMT in Schedule I effective May 1, 1971. MDMA, synthesized by Merck in 1912 but not widely used until the 1970s, remained unscheduled until July 1, 1985, when the DEA used emergency scheduling authority under 21 U.S.C. § 811(h) to place it in Schedule I. A group of psychiatrists and researchers challenged this scheduling through an administrative hearing before DEA Administrative Law Judge Francis Young, who recommended in May 1986 that MDMA be placed in Schedule III to allow continued therapeutic use. DEA Administrator John Lawn rejected this recommendation, and MDMA entered permanent Schedule I status on March 23, 1988.

The Research Desert: 1985-2000

Schedule I placement created nearly insurmountable barriers to research. Scientists seeking to study Schedule I substances must obtain a DEA Schedule I research registration, which requires extensive security measures including vault storage, alarm systems, and detailed record-keeping. The DEA also imposes manufacturing quotas under 21 U.S.C. § 826, limiting the total quantity of Schedule I substances that can be produced annually. For decades, the National Institute on Drug Abuse held a monopoly on supplying cannabis for research, and similar bottlenecks affected psychedelic research. Rick Doblin founded the Multidisciplinary Association for Psychedelic Studies in 1986 specifically to navigate the regulatory pathway for MDMA-assisted psychotherapy. The organization spent two decades building relationships with the FDA and DEA, conducting preclinical studies, and developing protocols that would satisfy regulatory requirements.

The FDA Reopens the Door: 2000-2017

The FDA approved the first Phase 1 safety study of MDMA in healthy volunteers in 2000, marking the first legal administration of MDMA to humans in the United States since 1985. Johns Hopkins University researchers published a landmark safety study of psilocybin in 2006 in Psychopharmacology, demonstrating that the compound could be administered safely in controlled settings and produced mystical-type experiences correlated with long-term positive changes. The FDA granted Breakthrough Therapy designation to MDMA-assisted psychotherapy for PTSD on August 16, 2017, and to psilocybin therapy for treatment-resistant depression on October 23, 2018 (Compass Pathways) and November 27, 2019 (Usona Institute). Breakthrough Therapy designation, created by the FDA Safety and Innovation Act of 2012, allows more intensive FDA guidance and potentially faster review for drugs treating serious conditions where preliminary clinical evidence shows substantial improvement over existing therapies.

State-Level Decriminalization and Legalization: 2020-2026

Oregon voters approved Measure 109 on November 3, 2020, creating the nation's first legal psilocybin therapy program, which launched on June 1, 2023. The Oregon Health Authority licensed 19 service centers and 89 facilitators in the program's first year. Oregon voters also approved Measure 110, which decriminalized possession of small amounts of all drugs, though the legislature partially repealed this in 2024. Colorado voters passed Proposition 122 on November 8, 2022, legalizing psilocybin and psilocin for therapeutic use and decriminalizing DMT, ibogaine, and mescaline (except from peyote). The Colorado Department of Regulatory Agencies began accepting applications for healing centers on September 1, 2024. California, Massachusetts, and Washington advanced various psychedelic reform bills between 2023 and 2026, though none achieved the comprehensive frameworks of Oregon or Colorado. More than 100 cities and counties, including Seattle, Oakland, Santa Cruz, Ann Arbor, and Washington D.C., passed resolutions deprioritizing enforcement of psychedelic possession laws.

The 2026 Regulatory Collision

On September 16, 2026, the FDA held a public hearing titled "Psychedelic Drug Development: Scientific and Regulatory Issues" at its White Oak campus in Silver Spring, Maryland. The hearing addressed clinical trial design, informed consent, therapist training, integration protocols, and post-approval access models. More than 60 speakers testified, including researchers, pharmaceutical executives, patient advocates, and indigenous medicine practitioners. One week later, on September 23, 2026, the DEA published notices of intent to schedule several novel psychedelic compounds, including synthetic tryptamines and phenethylamines that have appeared in research literature. The timing created immediate controversy, with advocates noting the contradiction between the FDA's efforts to expand access and the DEA's moves to restrict it further.

Key Players in the Federal Scheduling Debate

Drug Enforcement Administration

The DEA holds statutory authority under 21 U.S.C. § 811 to add substances to the controlled substances schedules, remove them, or transfer them between schedules. The agency operates within the Department of Justice and prioritizes drug control and public safety. Administrator Anne Milgram, who has led the agency since June 2021, oversees scheduling decisions through the DEA's Diversion Control Division. The DEA's scheduling process requires an eight-factor analysis under 21 U.S.C. § 811(c), examining actual or relative potential for abuse, scientific evidence of pharmacological effect, current scientific knowledge, history and current pattern of abuse, scope, duration and significance of abuse, risk to public health, psychic or physiological dependence liability, and whether the substance is an immediate precursor of a controlled substance. The DEA must request a scientific and medical evaluation from the Department of Health and Human Services, which the FDA conducts.

Food and Drug Administration

The FDA regulates drug development and approval under the Federal Food, Drug, and Cosmetic Act, evaluating safety and efficacy without regard to DEA scheduling. Commissioner Robert Califf, who returned to lead the agency in February 2022, has supported evidence-based approaches to psychedelic therapy development. The FDA's Center for Drug Evaluation and Research, led by Director Patrizia Cavazzoni, oversees the Investigational New Drug application process that allows clinical trials of Schedule I substances. The FDA's September 2026 hearing signaled openness to novel regulatory approaches for psychedelic therapies, including Risk Evaluation and Mitigation Strategies that could address concerns about misuse while enabling access. The agency has approved more than 30 clinical trials of psilocybin, MDMA, LSD, DMT, and ibogaine since 2020.

Multidisciplinary Association for Psychedelic Studies

MAPS, founded by Rick Doblin in 1986, has invested more than $140 million in MDMA-assisted therapy development. The organization completed six Phase 2 trials and two Phase 3 trials, submitting a New Drug Application to the FDA in December 2023. The FDA's Psychopharmacologic Drugs Advisory Committee reviewed the application in June 2024, voting 10-1 that the benefits outweigh the risks, though the FDA issued a Complete Response Letter in August 2024 requesting additional data on therapist training protocols and long-term safety monitoring. MAPS Public Benefit Corporation, the for-profit entity conducting the FDA approval process, has committed to making MDMA-assisted therapy available at cost to veterans and first responders if approved.

Compass Pathways

This London-based pharmaceutical company, founded in 2016, received Breakthrough Therapy designation for its proprietary synthetic psilocybin formulation, COMP360, in October 2018. The company completed a Phase 2b trial in 2021 showing that a single 25-milligram dose of psilocybin with psychological support produced rapid and sustained antidepressant effects in treatment-resistant depression. Compass initiated Phase 3 trials in 2023 and projects potential FDA approval in 2027. The company went public on the Nasdaq in September 2020, raising $127 million at a valuation exceeding $1 billion. Compass has faced criticism from some advocates for patenting aspects of psilocybin therapy, including synthetic formulations and treatment protocols.

Usona Institute

This nonprofit medical research organization, founded in 2014, received Breakthrough Therapy designation for psilocybin therapy for major depressive disorder in November 2019. Usona has committed to making its psilocybin formulation available royalty-free if approved, contrasting with Compass Pathways' proprietary approach. The organization completed a Phase 2 trial in 2023 and is planning Phase 3 studies.

Congressional Advocates and Opposition

Representative Alexandria Ocasio-Cortez and Senator Cory Booker introduced the Breakthrough Therapies Act in March 2024, which would require the DEA to expedite Schedule III placement for any drug receiving FDA Breakthrough Therapy designation. The bill has 47 House cosponsors and 12 Senate cosponsors but has not advanced to committee votes. Representative Andy Biggs and Senator Tom Cotton have opposed psychedelic reform, arguing that Schedule I placement protects public health and that state-level legalization violates the Controlled Substances Act's federal supremacy provisions. The Congressional opposition focuses on concerns about recreational diversion, long-term psychiatric risks, and the precedent for broader drug policy reform.

Legal and Regulatory Framework

The federal scheduling system, established by the Controlled Substances Act of 1970 and codified at 21 U.S.C. § 801 et seq., creates the legal architecture governing psychedelic research, medical use, and criminal penalties.

The Five-Schedule System

Schedule I substances, defined in 21 U.S.C. § 812(b)(1), must meet three criteria: high potential for abuse, no currently accepted medical use in treatment in the United States, and lack of accepted safety for use under medical supervision. Penalties for Schedule I trafficking include up to 20 years imprisonment for first offense under 21 U.S.C. § 841(b)(1)(C), with enhanced penalties for larger quantities or prior convictions. Schedule II substances have high abuse potential but currently accepted medical use with severe restrictions. Examples include cocaine, methamphetamine, and fentanyl. Schedule III through V represent progressively lower abuse potential and regulatory burden.

The Scheduling Process

Under 21 U.S.C. § 811(a), the Attorney General (who has delegated authority to the DEA Administrator) may initiate scheduling proceedings, or proceedings may be initiated by the Department of Health and Human Services or by petition from any interested party. The DEA must request a scientific and medical evaluation from HHS, which the FDA conducts through an eight-factor analysis. The Administrative Procedure Act, 5 U.S.C. § 553, governs the scheduling process, requiring notice in the Federal Register, opportunity for public comment, and a final rule published at least 30 days before the effective date. For substances without existing medical use, the DEA may use expedited scheduling. Emergency scheduling under 21 U.S.C. § 811(h) allows temporary Schedule I placement for one year, extendable for six months, when necessary to avoid imminent hazard to public safety.

Rescheduling and Descheduling

The same process under 21 U.S.C. § 811 applies to moving substances between schedules or removing them entirely. The DEA has rescheduled substances in response to FDA approval—for example, moving Epidiolex, a CBD-based drug, to Schedule V after FDA approval in 2018, and descheduling it entirely in 2020. The FDA approval of a drug containing a Schedule I substance creates regulatory tension. Under 21 U.S.C. § 812(b)(1), a substance cannot simultaneously have "no currently accepted medical use" and be an FDA-approved medication. The DEA has discretion to initiate rescheduling but is not required to do so immediately upon FDA approval.

Research Registration Requirements

Researchers studying Schedule I substances must obtain a DEA Schedule I research registration under 21 C.F.R. § 1301. Requirements include a physical security system meeting DEA specifications, vault or safe storage, alarm systems, background checks for all personnel with access, and detailed record-keeping of all acquisitions, uses, and dispositions. Registration costs $888 for three years, but compliance infrastructure typically costs $100,000 to $500,000 to establish. Manufacturing quotas under 21 U.S.C. § 826 limit the total quantity of Schedule I substances produced annually. The DEA publishes proposed aggregate production quotas in the Federal Register each year, accepting public comment before finalizing quotas. Researchers have reported that quota limitations create supply bottlenecks that delay clinical trials.

State-Federal Conflicts and Supremacy Clause

The Supremacy Clause of the U.S. Constitution, Article VI, Clause 2, establishes that federal law preempts conflicting state law. The Controlled Substances Act contains no explicit preemption provision, but courts have held that state legalization does not eliminate federal criminal liability. In Gonzales v. Raich, 545 U.S. 1 (2005), the Supreme Court held that the Commerce Clause grants Congress authority to prohibit local cultivation and possession of cannabis even in states where medical use is legal. However, the federal government has limited resources to enforce drug laws and typically relies on state and local cooperation. The Rohrabacher-Farr Amendment, first enacted in 2014 and renewed annually, prohibits the Department of Justice from using funds to prevent states from implementing medical cannabis laws. No similar protection exists for state psychedelic programs, creating legal uncertainty for Oregon and Colorado operators.

State-by-State Breakdown of Psychedelic Policy

As of September 2026, two states have legalized psilocybin therapy programs, more than a dozen have active decriminalization or legalization bills, and more than 100 local jurisdictions have deprioritized enforcement.

Oregon

Oregon operates the nation's first licensed psilocybin therapy program under Measure 109, approved November 3, 2020. The Oregon Health Authority licenses service centers where adults 21 and older can consume psilocybin under supervision of licensed facilitators. No medical diagnosis is required. The program launched June 1, 2023, with 19 licensed service centers and 89 facilitators as of September 2026. Sessions cost between $1,500 and $3,500 and include preparation meetings, a supervised psilocybin experience lasting six to eight hours, and integration sessions. The Oregon Psilocybin Services Section within the Oregon Health Authority regulates manufacturing, testing, service centers, and facilitators. Possession limits do not apply within licensed facilities, but removing psilocybin from service centers remains illegal. Oregon also passed Measure 110 in November 2020, decriminalizing possession of small amounts of all drugs and replacing criminal penalties with $100 fines and health assessments. The Oregon Legislature partially repealed Measure 110 in 2024, recriminalizing public drug use while maintaining treatment-focused approaches for private possession.

Colorado

Colorado voters approved Proposition 122 on November 8, 2022, by 53 percent to 47 percent. The measure legalized psilocybin and psilocin for therapeutic use in licensed healing centers and decriminalized personal possession and home cultivation of psilocybin, psilocin, DMT, ibogaine, and mescaline (except from peyote, which remains protected for Native American Church use). The Colorado Department of Regulatory Agencies began accepting applications for healing centers on September 1, 2024. As of September 2026, Colorado has licensed 12 healing centers and 67 facilitators. Unlike Oregon, Colorado requires a licensed healthcare provider to be involved in treatment plans for clients with certain medical or psychiatric conditions. Personal possession limits under Proposition 122 allow up to four grams of psilocybin or psilocin, and cultivation of up to 12 plants for personal use. Sharing without remuneration is legal, but sales outside licensed facilities remain criminal offenses.

California

California's Senate Bill 58, which would have decriminalized possession and social sharing of psilocybin, psilocin, DMT, ibogaine, and mescaline, passed the legislature in September 2023 but was vetoed by Governor Gavin Newsom on October 7, 2023. Newsom cited the need for a regulated therapeutic framework rather than simple decriminalization. In 2024, California's Senate Bill 1012 proposed creating a regulated psilocybin therapy program similar to Oregon's model, but the bill stalled in the Assembly Appropriations Committee. As of September 2026, California has no statewide psychedelic reform, though Oakland, Santa Cruz, and Arcata have passed local decriminalization resolutions.

Massachusetts

Massachusetts advanced House Bill 3605 in 2024, which would legalize and regulate the therapeutic use of psilocybin and create a commission to study other psychedelics. The bill passed the House in July 2024 but faced opposition in the Senate. As of September 2026, the bill remains in conference committee. Cambridge, Somerville, Northampton, and Easthampton have passed local resolutions making enforcement of psychedelic possession laws the lowest priority for law enforcement.

Washington

Washington's Senate Bill 5660, introduced in January 2023, would have created a psilocybin therapy program modeled on Oregon's system. The bill passed the Senate Health and Long-Term Care Committee but did not advance to a floor vote. Seattle passed Resolution 32021 in October 2021, making enforcement of laws prohibiting cultivation and possession of entheogenic plants among the city's lowest law enforcement priorities.

Other States with Active Reform Efforts

Connecticut, Maryland, Missouri, New York, Texas, and Utah have active bills or ballot initiatives in various stages as of September 2026. Most proposals focus on psilocybin therapy programs or decriminalization of possession, with some including broader lists of psychedelics. Texas presents a unique case, with Republican state legislators including Representative Alex Dominguez sponsoring House Bill 1802 in 2023 to legalize psilocybin therapy for veterans with PTSD. The bill gained bipartisan support but did not advance before the legislative session ended.

Market and Business Implications

The psychedelic pharmaceutical and therapy sectors attracted $2.4 billion in investment between 2019 and 2025, but DEA scheduling decisions could eliminate or accelerate this market depending on regulatory outcomes.

Pharmaceutical Development Sector

Publicly traded psychedelic pharmaceutical companies including Compass Pathways, MindMed, Cybin, and Atai Life Sciences have a combined market capitalization exceeding $3 billion as of September 2026, down from a peak of $8 billion in 2021. These companies are developing synthetic psychedelics, novel analogs, and proprietary formulations designed to reduce adverse effects or shorten duration while maintaining therapeutic benefits. Schedule I placement of novel compounds directly impacts this sector by increasing research costs, limiting manufacturing capacity through DEA quotas, and creating uncertainty about commercial viability. If the DEA schedules compounds currently in preclinical development, companies may abandon those programs entirely, redirecting capital to compounds with clearer regulatory pathways. Conversely, if the FDA approves MDMA or psilocybin therapies and the DEA reschedules these substances to Schedule II or III, the commercial market could expand rapidly. Analysts project that the psychedelic therapy market could reach $10.75 billion by 2027 if regulatory barriers fall, according to Data Bridge Market Research estimates.

Therapy and Service Center Sector

Oregon's psilocybin service centers reported total revenue of approximately $8.5 million in the program's first year, serving an estimated 3,000 clients. The average session cost of $2,500 limits access to affluent clients, creating equity concerns. Colorado's newer program has not yet released comprehensive revenue data. If the DEA maintains or expands Schedule I classifications, state-licensed programs face ongoing federal legal risk. While the Department of Justice has not prosecuted state-licensed cannabis businesses in states with comprehensive regulatory frameworks since the 2013 Cole Memorandum (rescinded in 2018 but largely followed in practice), no formal policy protects psychedelic service centers. Operators carry federal criminal liability, complicating banking access, insurance coverage, and interstate commerce. The therapy sector also includes ketamine clinics, which operate legally because ketamine is Schedule III. More than 500 ketamine clinics operate nationwide as of 2026, generating an estimated $500 million annually. These clinics provide a business model for psychedelic therapy if compounds move to Schedule III, but Schedule I or II placement would impose significantly greater restrictions.

Impact on Medical Systems and Payers

If the FDA approves psychedelic therapies, Medicare, Medicaid, and private insurers will face coverage decisions. The high cost of psychedelic-assisted therapy—including preparation sessions, supervised dosing, and integration—could range from $5,000 to $15,000 per treatment course. Insurers typically cover FDA-approved medications, but the therapy component creates novel reimbursement questions. The Centers for Medicare & Medicaid Services would need to establish billing codes for psychedelic-assisted therapy, including codes for preparation, dosing supervision, and integration. The American Medical Association's Current Procedural Terminology Editorial Panel would likely create new codes, similar to the process for other novel therapies. Veterans Affairs represents a critical payer, with more than 9 million enrolled veterans. The VA has funded observational studies of psychedelic therapy but has not committed to coverage if FDA approval occurs. Congressional legislation including the TREAT Act, introduced in 2023, would require the VA to cover breakthrough-designated therapies for veterans, potentially including MDMA for PTSD.

Investment and Capital Markets

Venture capital investment in psychedelic companies peaked at $791 million in 2021, according to Psychedelic Alpha, then declined to $142 million in 2023 and $89 million in 2025 as regulatory timelines extended and FDA approval delays mounted. The DEA's September 2026 scheduling actions could further contract investment, as capital flows to sectors with clearer regulatory pathways. Special purpose acquisition companies brought several psychedelic companies public in 2020-2021, but most have underperformed. Compass Pathways, the sector's largest public company, trades at approximately 60 percent below its 2020 IPO price as of September 2026. Institutional investors including pension funds and university endowments have largely avoided the sector due to federal illegality and regulatory uncertainty. If the DEA reschedules approved therapies to Schedule III, institutional capital could enter the market, potentially adding billions in investment.

What Experts Say

Researchers, clinicians, policy experts, and patient advocates have expressed concern that the DEA's scheduling actions contradict the FDA's efforts to expand access to psychedelic therapies. Rick Doblin, founder of the Multidisciplinary Association for Psychedelic Studies, said in a September 2026 statement that the regulatory conflict reflects institutional dysfunction. According to Doblin, the FDA's scientific review process has demonstrated that MDMA-assisted therapy meets safety and efficacy standards for PTSD, while the DEA's scheduling decisions are driven by drug control priorities that do not account for medical evidence. Dr. Rachel Yehuda, director of the Center for Psychedelic Psychotherapy and Trauma Research at the Icahn School of Medicine at Mount Sinai, has emphasized that veterans with treatment-resistant PTSD face life-threatening conditions that require novel interventions. According to Yehuda, the DEA's scheduling authority should not override the FDA's medical determinations when patients have exhausted conventional treatments. Dr. Charles Grob, professor of psychiatry at UCLA School of Medicine and a pioneer in modern psychedelic research, has noted that the current scheduling system was created in 1970 based on political considerations rather than scientific evidence. According to Grob, the eight-factor analysis required by 21 U.S.C. § 811(c) should lead to Schedule III or IV placement for psychedelics with demonstrated medical utility and manageable safety profiles. Ismail Ali, policy and advocacy counsel at the Multidisciplinary Association for Psychedelic Studies, has argued that the Controlled Substances Act's definition of Schedule I is internally contradictory when applied to substances undergoing FDA approval. According to Ali, a substance cannot simultaneously have no accepted medical use and be the subject of FDA Breakthrough Therapy designation. Dr. Matthew Johnson, professor of psychiatry and behavioral sciences at Johns Hopkins University School of Medicine, has stated that psilocybin's safety profile in clinical settings is well-established across more than 30 studies involving more than 1,500 participants. According to Johnson, the primary risks are psychological distress during sessions, which is managed through screening and therapeutic support, not long-term psychiatric harm. Critics of psychedelic medicalization, including some indigenous medicine practitioners and harm reduction advocates, have expressed concern that pharmaceutical companies are appropriating traditional practices and creating proprietary formulations that will be unaffordable for marginalized communities. According to these perspectives, decriminalization and community-based access models better serve public health than pharmaceutical monopolies enforced through patent and scheduling systems. Law enforcement organizations including the Drug Enforcement Administration Association, which represents DEA agents, have maintained that Schedule I placement is necessary to prevent diversion to recreational markets. According to this view, state-level legalization creates enforcement challenges and sends mixed messages about drug risks, particularly to young people.

What's Next: Decision Points and Scenarios

The next 12 to 24 months will determine whether psychedelic medicine becomes widely available or remains locked in Schedule I prohibition.

Immediate Timeline: DEA Scheduling Proceedings

The DEA's September 23, 2026 notices of intent to schedule several psychedelic compounds will proceed through the Administrative Procedure Act's notice-and-comment process. The agency typically allows 60 days for public comment after publishing a Notice of Proposed Rulemaking in the Federal Register. Based on historical timelines, final scheduling rules could be published in early 2027, with effective dates 30 days later. Affected parties including pharmaceutical companies, research institutions, and advocacy organizations are expected to submit detailed comments arguing that scheduling would obstruct medical research and contradict the FDA's Breakthrough Therapy designations. The DEA must respond to substantive comments but is not required to change its proposed scheduling based on public input.

FDA Approval Decisions: 2027-2028

MAPS Public Benefit Corporation is expected to resubmit its New Drug Application for MDMA-assisted therapy for PTSD in late 2026 or early 2027, addressing the FDA's Complete Response Letter requesting additional data on therapist training and long-term safety monitoring. If the resubmission is complete, the FDA has six months to review and approve or issue another Complete Response Letter. Approval could come as early as mid-2027. Compass Pathways projects potential FDA approval for COMP360 psilocybin therapy for treatment-resistant depression in 2027 or 2028, pending completion of Phase 3 trials. Usona Institute's psilocybin program follows a similar timeline. If the FDA approves any psychedelic therapy while the substance remains in Schedule I, the regulatory contradiction will force action. The DEA could initiate rescheduling proceedings, Congress could legislate a solution, or the agencies could remain in conflict, creating a situation where a drug is simultaneously FDA-approved and federally prohibited for medical use outside research settings.

Congressional Action Scenarios

The Breakthrough Therapies Act, if passed, would require the DEA to place any drug with FDA Breakthrough Therapy designation in Schedule III within 90 days of FDA approval. The bill has bipartisan support but faces opposition from drug control advocates. Congressional action is more likely if the FDA approves MDMA or psilocybin and the DEA refuses to reschedule, creating a crisis that demands legislative resolution. Alternative legislative approaches include appropriations riders prohibiting the DEA from using funds to interfere with state psychedelic programs, similar to the Rohrabacher-Farr Amendment for cannabis. Such riders require annual renewal and do not change underlying law, but they provide practical protection for state-licensed operators.

Litigation Possibilities

If the DEA schedules compounds currently in clinical trials, pharmaceutical companies could challenge the scheduling under the Administrative Procedure Act, arguing that the decision is arbitrary and capricious under 5 U.S.C. § 706. Courts typically defer to agency expertise in scientific determinations, but plaintiffs could argue that the DEA ignored FDA findings or failed to adequately consider the eight-factor analysis. State governments could challenge federal scheduling as exceeding Commerce Clause authority or violating principles of federalism, though Gonzales v. Raich established broad federal power to regulate drugs. A more promising legal theory might argue that the Controlled Substances Act's Schedule I criteria are unconstitutionally vague as applied to